Akina — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Akina, Inc. is a privately held, revenue-generating research and services company specializing in polymer-based drug delivery systems. Founded by Dr. Kinam Park, it leverages its proximity to Purdue University to offer critical reagents (PolySciTech) and contract R&D/analytical services (Akinalytics) to the pharmaceutical and biotech research community. While not a traditional therapeutic developer, Akina supports the preclinical and early clinical pipeline of other companies through its materials, formulations expertise, and connection to a GMP manufacturing partner, Midwest GMP, LLC. Its business model is built on enabling advanced drug delivery research for clients.

Drug DeliverySmall Molecules

Technology Platform

Expertise in polymer synthesis, characterization, and formulation for controlled-release drug delivery systems. Platform encompasses proprietary biodegradable polymers, analytical services, and formulation know-how.

Opportunities

Growing demand for complex drug delivery solutions for biologics and new modalities creates a sustained need for Akina's specialized polymers and formulation expertise.

The connection to Midwest GMP allows Akina to capture value across the translational spectrum, from early research to early clinical manufacturing.

Expansion of its product catalog and service offerings into adjacent areas like medical devices or diagnostics presents additional growth avenues.

Risk Factors

Revenue is dependent on the R&D budgets of academic and biopharma clients, making it vulnerable to economic downturns.

Competition from larger chemical suppliers and global CROs could pressure pricing and market share.

The business relies on retaining key scientific personnel and maintaining a reputation for cutting-edge expertise in a rapidly evolving field.

Competitive Landscape

Akina competes in niche segments against larger players like Sigma-Aldrich (now MilliporeSigma) in research polymers and large global CROs (e.g., Charles River Labs, LabCorp) in analytical services. Its differentiation lies in deep specialization in polymer-based drug delivery, a curated product portfolio, and founder-led scientific credibility. It also competes with smaller, specialized formulation CROs and academic spin-outs.

More companies in Drug Delivery & Formulation →More companies in United States →